# High-Dose Methotrexate in Treating Young Patients With Residual Ependymoma

> **NCT00287924** · PHASE2 · UNKNOWN · sponsor: **Children's Cancer and Leukaemia Group** · enrollment: 29 (estimated)

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **DRUG:** methotrexate
- **PROCEDURE:** adjuvant therapy

## Key facts

- **NCT ID:** NCT00287924
- **Lead sponsor:** Children's Cancer and Leukaemia Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2005-03
- **Primary completion:** 2010-03
- **Final completion:** —
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2013-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00287924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00287924, "High-Dose Methotrexate in Treating Young Patients With Residual Ependymoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00287924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*